Autoimmunity reviews最新文献

{"title":"Insights into the complexities of Citrullination: From immune regulation to autoimmune disease","authors":"Jiawei Wang ,&nbsp;Jinlin Miao ,&nbsp;Ping Zhu","doi":"10.1016/j.autrev.2024.103734","DOIUrl":"10.1016/j.autrev.2024.103734","url":null,"abstract":"<div><div>Citrullination, a post-translational modification that changes arginine to citrulline in proteins, is vital for immune response modulation and cell signaling. Catalyzed by peptidyl arginine deiminases (PADs), citrullination is linked to various diseases, particularly autoimmune disorders like rheumatoid arthritis (RA). Citrullinated proteins can trigger the production of anti-citrullinated protein antibodies (ACPAs), included in RA classification criteria. The immune response to citrullination involves both innate and adaptive immunity, affecting monocytes/macrophages, neutrophils, dendritic cells, natural killer cells, B cells, and T cells. Citrullination contributes to disease development in RA and other conditions such as multiple sclerosis, sepsis, and cancer. Therapeutic strategies targeting citrullination and its effects are being explored, including B cell depletion therapies, T cell-directed approaches, PAD inhibitors, and citrullinated peptide-based vaccines. Understanding the interplay between citrullination and the immune system may lead to novel diagnostic tools and targeted therapies for autoimmune diseases and beyond.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 3","pages":"Article 103734"},"PeriodicalIF":9.2,"publicationDate":"2024-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142885220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"T lymphocyte plasticity in chronic inflammatory diseases: The emerging role of the Ikaros family as a key Th17-Treg switch","authors":"A. Ramón-Vázquez ,&nbsp;P. Flood ,&nbsp;T.L. Cashman ,&nbsp;P. Patil ,&nbsp;S. Ghosh","doi":"10.1016/j.autrev.2024.103735","DOIUrl":"10.1016/j.autrev.2024.103735","url":null,"abstract":"<div><div>T helper (Th) 17 and regulatory T (Treg) cells are highly plastic CD4⁺ Th cell subsets, being able not only to actively adapt to their microenvironment, but also to interconvert, acquiring mixed identity markers. These phenotypic changes are underpinned by transcriptional control mechanisms, chromatin reorganization events and epigenetic modifications, that can be hereditable and stable over time. The Ikaros family of transcription factors have a predominant role in T cell subset specification through mechanisms of transcriptional program regulation that enable phenotypical diversification. They are crucial factors in maintaining Th17/Treg balance and therefore, homeostatic conditions in the tissues. However, they are also implicated in pathogenic processes, where their transcriptional repression contributes to the control of autoimmune processes. In this review, we discuss how T cell fate, specifically in humans, is regulated by the Ikaros family and its interplay with additional factors like the Notch signaling pathway, gut microbiota and myeloid-T cell interactions. Further, we highlight how the transcriptional activity of the Ikaros family impacts the course of T cell mediated chronic inflammatory diseases like rheumatoid and psoriatic arthritis, inflammatory bowel disease, systemic lupus erythematosus and multiple sclerosis. We conclude by discussing recently developed therapeutics designed to target Ikaros family members.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 3","pages":"Article 103735"},"PeriodicalIF":9.2,"publicationDate":"2024-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142885222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Macrophage metabolic reprogramming: A trigger for cardiac damage in autoimmune diseases","authors":"Lin Liu ,&nbsp;Minghao Li ,&nbsp;Chunyu Zhang ,&nbsp;Yi Zhong ,&nbsp;Bin Liao ,&nbsp;Jian Feng ,&nbsp;Li Deng","doi":"10.1016/j.autrev.2024.103733","DOIUrl":"10.1016/j.autrev.2024.103733","url":null,"abstract":"<div><div>Macrophage metabolic reprogramming has a central role in the progression of autoimmune and auto-inflammatory diseases. The heart is a major target organ in many autoimmune conditions and can sustain functional and structural impairments, potentially leading to irreversible cardiac damage. There is mounting clinical evidence pointing to a link between autoimmune disease and cardiac damage. However, this association remains poorly understood, and numerous patients do not receive appropriate preventive measures, which poses serious cardiovascular risks and significantly impacts their quality of life. This review discusses the relationship between macrophage metabolic reprogramming and cardiac damage in patients with autoimmune diseases and the role of adaptive immunity in macrophage reprogramming. It also provides an overview of the immunosuppressive therapies used at present. Exploiting the properties of macrophage reprogramming could lead to development of novel treatments for patients with autoimmune-related cardiac damage.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 3","pages":"Article 103733"},"PeriodicalIF":9.2,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142880917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Crystalline silica on the lung–environment interface: Impact on immunity, epithelial cells, and therapeutic perspectives for autoimmunity","authors":"Gaël Galli ,&nbsp;Damien Leleu ,&nbsp;Agathe Depaire ,&nbsp;Patrick Blanco ,&nbsp;Cécile Contin-Bordes ,&nbsp;Marie-Elise Truchetet","doi":"10.1016/j.autrev.2024.103730","DOIUrl":"10.1016/j.autrev.2024.103730","url":null,"abstract":"<div><div>Crystalline silica (the most abundant form of silicon dioxide) is a natural element that is ubiquitous in the Earth's crust. Chronic personal or professional exposure has been implicated in various pathologies, including silicosis and autoimmune diseases since the early 20th century. More recently, a specific pathogenic role for crystalline silica has been identified through its impact on lung epithelial cells as well as immune cells present at this organism barrier. This review summarizes the current <em>in vitro</em> and <em>in vivo</em> knowledge regarding the physiopathology of crystalline silica at the lung–environment interface, discusses its effects on innate and adaptive immune cells and epithelial cells, and reviews current therapeutic perspectives explored in mouse models to alleviate its impact, especially on autoimmune phenotypes.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 3","pages":"Article 103730"},"PeriodicalIF":9.2,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deucravacitinib shows superior efficacy and safety in cutaneous lupus erythematosus compared to various biologics and small molecules – A systematic review and meta-analysis","authors":"Laura Anna Bokor ,&nbsp;Katalin Martyin ,&nbsp;Máté Krebs ,&nbsp;Noémi Ágnes Galajda ,&nbsp;Fanni Adél Meznerics ,&nbsp;Bence Szabó ,&nbsp;Péter Hegyi ,&nbsp;Kende Lőrincz ,&nbsp;Norbert Kiss ,&nbsp;András Bánvölgyi ,&nbsp;Bernadett Hidvégi","doi":"10.1016/j.autrev.2024.103723","DOIUrl":"10.1016/j.autrev.2024.103723","url":null,"abstract":"<div><h3>Background</h3><div>Novel therapies for cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) demonstrated efficacy and safety in previous trials. However, data on the comparison of these treatments is still lacking, limiting their integration into clinical practice. Therefore, our aim is to perform a systematic review and network meta-analysis to compare the efficacy and safety of novel systemic therapies in CLE.</div></div><div><h3>Methods</h3><div>A systematic search was performed across PubMed, Embase, and CENTRAL on November 25, 2023, to identify studies involving patients with CLE or SLE with active skin involvement treated with novel systemic therapies. The primary outcomes assessed were the proportion of patients achieving the Cutaneous Lupus Erythematosus Disease Area and Severity Index-50 (CLASI-50), the change in CLASI-A, the occurrence of adverse events (AEs), and serious adverse events (SAEs).</div></div><div><h3>Results</h3><div>18,280 records were retrieved, of which 53 met the inclusion criteria. Deucravacitinib showed significantly greater efficacy in achieving the CLASI50 compared to placebo (OR: 8.28, 95 % CI: 2.22–30.91). Both litifilimab (OR: 2.54, 95 % CI: 1.20–5.40) and anifrolumab (OR: 2.25, 95 % CI: 1.23–4.14) were also significantly more effective than placebo. No significant differences were observed in the occurrence of AEs and SAEs between these therapeutics and placebo.</div></div><div><h3>Conclusion</h3><div>Anifrolumab and litifilimab are effective and safe treatment options in CLE. However, deucravacitinib demonstrated superior efficacy and safety with fewer adverse events compared to anifrolumab<em>.</em> CLE patients who have shown an inadequate response to first- and second-line treatments may benefit from the incorporation of deucravacitinib into their treatment regimens.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 3","pages":"Article 103723"},"PeriodicalIF":9.2,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142852383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FcRn inhibitors: Transformative advances and significant impacts on IgG-mediated autoimmune diseases","authors":"Lina Zhu,&nbsp;Lanjun Li,&nbsp;Jun Wu","doi":"10.1016/j.autrev.2024.103719","DOIUrl":"10.1016/j.autrev.2024.103719","url":null,"abstract":"<div><div>Pathogenic IgG autoantibodies play a crucial role in the pathogenesis of autoimmune diseases, and removal of pathogenic IgG autoantibodies is an important therapeutic approach and tool for such diseases. The neonatal Fc receptor (FcRn) interacts with IgG and protects it from lysosomal degradation. FcRn inhibitors accelerate the clearance of IgG antibodies, including pathogenic IgG autoantibodies, by targeting and blocking the binding of FcRn to IgG. Theoretically, FcRn inhibitors can be applied for the treatment of IgG-mediated autoimmune diseases. With successful completion of multiple relevant clinical trials, key evidence-based data have been provided for FcRn inhibitors in the treatment of IgG-mediated autoimmune diseases, and several FcRn inhibitors have been approved for these indications. Additional trials are being planned or conducted. This review examines all available high-quality clinical trials of FcRn inhibitors assessing IgG-mediated autoimmune diseases.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 3","pages":"Article 103719"},"PeriodicalIF":9.2,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142821857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravenous immunoglobulin as a therapy for autoimmune conditions","authors":"Maria Giovanna Danieli ,&nbsp;Eleonora Antonelli ,&nbsp;Luca Gammeri ,&nbsp;Eleonora Longhi ,&nbsp;Maria Francesca Cozzi ,&nbsp;Davide Palmeri ,&nbsp;Sebastiano Gangemi ,&nbsp;Yehuda Shoenfeld","doi":"10.1016/j.autrev.2024.103710","DOIUrl":"10.1016/j.autrev.2024.103710","url":null,"abstract":"<div><div>Intravenous immunoglobulin (IVIg) is a medical preparation used as replacement therapy for patients with immunodeficiencies. Over time, IVIg's anti-inflammatory and immunomodulatory effects have been recognized, which have led to the approval of this therapy in the treatment of various pathologies, such as Kawasaki disease, immune thrombocytopenia, and Guillain-Barré syndrome. There are numerous studies in the literature regarding the off-label use of IVIg in the treatment of autoimmune diseases (e.g. myositis and vasculitis), and hematological disorders.</div><div>Since the role of immunoglobulins in fields other than replacement therapy is now consolidated, in this study we carried out a review of the literature to evaluate the main uses of IVIg therapy. We have focused our attention on the treatment of autoimmune, neurological, hematological, dermatological and pediatric diseases. Furthermore, our analysis of the literature also extended to the potential use of IVIg as an adjuvant treatment of long COVID-19.</div><div>From our analysis, we found consistent data about IVIg's effectiveness in treating numerous clinical conditions. Treatment with IVIg represents a second-line approach or a valid adjuvant to standard therapies capable of positively influencing the clinical course of many pathologies and reducing or avoiding side effects of standard therapies, with a good safety profile.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 1","pages":"Article 103710"},"PeriodicalIF":9.2,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142724095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acupuncture therapy in autoimmune diseases: A narrative review","authors":"Dorit Gamus ,&nbsp;Yehuda Shoenfeld","doi":"10.1016/j.autrev.2024.103709","DOIUrl":"10.1016/j.autrev.2024.103709","url":null,"abstract":"<div><div>We provide a narrative review of experimental and clinical evidence for the effect of acupuncture in autoimmune diseases, based on randomized controlled studies, systematic review and meta-analyses, published between the years 2000–2023.</div><div>Acupuncture in experimental models of rheumatoid arthritis (RA), multiple sclerosis, psoriasis, ulcerative colitis (UC) downregulated inflammatory cytokine expression, increased IL-10 expression, improved Treg cell differentiation, and also modulated macrophage polarization in RA and UC models. The anti-inflammatory effect of acupuncture in autoimmune disorders has been demonstrated to involve vagal-adrenal and cholinergic anti-inflammatory pathways. The analgesic effect of acupuncture involves both peripheral and central anti-nociceptive mechanisms.</div><div>Randomized controlled studies support the use of acupuncture in rheumatoid arthritis, fibromyalgia, Crohn's disease and in Sjogren's syndrome. Some evidence indicates that acupuncture may be beneficial as a symptomatic treatment for multiple sclerosis, myasthenia gravis, psoriasis and ankylosing spondylitis.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 2","pages":"Article 103709"},"PeriodicalIF":9.2,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between physical trauma and autoimmune articular and dermatological disorders","authors":"Aia Muhsen ,&nbsp;Adi Hertz ,&nbsp;Howard Amital","doi":"10.1016/j.autrev.2024.103711","DOIUrl":"10.1016/j.autrev.2024.103711","url":null,"abstract":"<div><h3>Objective</h3><div>This review investigates the association between physical trauma and the onset and progression of various inflammatory diseases, including psoriatic arthritis (PsA), rheumatoid arthritis (RA), spondyloarthropathies (SpA), and Familial Mediterranean Fever (FMF). In addition, we will refer to the linkage between physical injury and skin manifestations in patients with psoriasis, sarcoidosis and systemic sclerosis. The aim is to summarize the current evidence and explore the potential mechanisms through which trauma may affect these conditions.</div></div><div><h3>Methods</h3><div>A detailed literature review was conducted, focusing on studies linking physical trauma with the development of psoriasis, SpA, PsA, RA, FMF, systemic sclerosis and sarcoidosis. The review includes observational data, case reports, and experimental studies that highlight the impact of trauma on disease initiation and exacerbation.</div></div><div><h3>Results</h3><div>Physical trauma is implicated in the pathogenesis of several dermatological and rheumatological conditions. Biomechanical stress and microdamage at entheses contribute to the development of SpA. In PsA, trauma is associated with the onset of enthesitis and arthritis, supported by increased prevalence in affected patients and is often regarded as “deep Koebner phenomenon”. The Koebner phenomenon links skin trauma with psoriasis, where new lesions appear at injury sites. RA shows a notable association with physical trauma, with retrospective studies suggesting that trauma can trigger disease onset, although the exact mechanisms remain unclear. The concept of the synovio-entheseal complex is discussed in order to elucidate how mechanical stress and immune responses interplay in SpA. Physical exertion or injury might precipitate FMF attacks, though existing data remain limited. Sarcoidosis has been linked to tattoo-related trauma, suggesting a potential role of localized injury in sarcoid-like reactions. Several case reports describe the occurrence of dermatologic manifestations of scleroderma, including morphea in patients with localized disease and perifollicular hypopigmentation in patients with systemic sclerosis.</div></div><div><h3>Conclusion</h3><div>This review consolidates current evidence on the relationship between physical trauma and various inflammatory conditions, emphasizing the need for further research to fully understand these connections. These findings highlight the importance of considering trauma in the clinical management of these diseases and suggest avenues for future investigation.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 1","pages":"Article 103711"},"PeriodicalIF":9.2,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden of inflammatory bowel disease among elderly, 1990–2019: A systematic analysis based on the global burden of disease study 2019","authors":"Liji Chen ,&nbsp;Shaoyu Cheng ,&nbsp;Beiping Zhang ,&nbsp;Cailing Zhong","doi":"10.1016/j.autrev.2024.103708","DOIUrl":"10.1016/j.autrev.2024.103708","url":null,"abstract":"<div><h3>Aim</h3><div>The number of elderly patients with inflammatory bowel disease (IBD) has increased dramatically over the past few decades. Understanding the global burden of IBD in the elderly can provide a valuable basis for formulating future healthcare policies. This study aimed to comprehensively assess the global burden of IBD in the elderly from 1990 to 2019.</div></div><div><h3>Methods</h3><div>We extracted prevalence, incidence, disability-adjusted life-years (DALYs), and mortality data of older adults (60–89 years old) with IBD from 2010 to 2019 from the Global Burden of Disease (GBD) Study 2019, and analyzed in subgroups according to region, country, Socio-demographic Index (SDI), age group, and gender. Additionally, Trends in the global burden of IBD in old age from 1990 to 2019 were analyzed by calculating the estimated annual percentage change (EAPC) in the age-standardized rates (ASDs).</div></div><div><h3>Results</h3><div>From 1990 to 2019, the number of prevalent cases, incident cases, DALYs, and deaths of IBD in older adults increased significantly. Age-standardized rates of incidence, prevalence, DALYs, and mortality all trended downward. Americas, European regions, and high SDI countries had consistently high burdens. Middle SDI countries had the fastest growth in prevalence, incidence, and the fastest decline in DALYs, and mortality. The age-standardized rates of prevalence, incidence, and DALYs for IBD in the elderly were highest in the 60–64 age group, and age-standardized rates of mortality were highest in the 80–84 and 85–89 age groups. No gender differences were observed when stratified by gender.</div></div><div><h3>Conclusions</h3><div>IBD in older adults has become a global public health burden due to significant increases in the number of prevalent cases, incident cases, DALYs, and deaths. There are marked differences among regions, countries, and between different age groups. Public health practitioners should develop targeted policies to effectively reduce the disease burden of IBD in older adults.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 2","pages":"Article 103708"},"PeriodicalIF":9.2,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}